Comment on

• A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

  Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S. Aapro M, et al. Ann Oncol. 2014 Jul;25(7):1328-1333. doi: 10.1093/annonc/mdu101. Epub 2014 Mar 5. Ann Oncol. 2014. PMID: 24603643 Free PMC article. Clinical Trial.
• Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

  Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ. Hesketh PJ, et al. Ann Oncol. 2014 Jul;25(7):1340-1346. doi: 10.1093/annonc/mdu110. Epub 2014 Mar 7. Ann Oncol. 2014. PMID: 24608196 Free PMC article. Clinical Trial.
• A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

  Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K. Gralla RJ, et al. Ann Oncol. 2014 Jul;25(7):1333-1339. doi: 10.1093/annonc/mdu096. Epub 2014 Mar 14. Ann Oncol. 2014. PMID: 24631949 Free PMC article. Clinical Trial.